{"type":"trials","record":{"id":28325,"source_id":"clinicaltrials-gov","external_id":"NCT07249216","title":"Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting","brief_summary":"Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40% have a suboptimal response. In this study, the investigators want to identify other factors (beyond VEGF) that might be driving the disease in these non-responding patients. By looking at samples from inside the eye (vitreous humor) and comparing \"good responders\" to \"suboptimal responders\", the investigators hope to find potential new treatment approaches or biomarkers for nAMD.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Singapore National Eye Centre","enrollment":117,"countries":["Singapore"],"start_date":"2025-07-18","completion_date":"2029-07-01","last_update_date":"2026-09-16","source_url":"https://clinicaltrials.gov/study/NCT07249216","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T00:17:13.08831+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"M-VIVA","age_range":"50 Years","comparator":null,"organization":"Singapore National Eye Centre","interventions":["Faricimab","Ranibizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Difference in vitreous biomarker concentrations between responders and non-responders — 12 weeks","Change in concentration of inflammatory and angiogenic biomarkers in vitreous humor from baseline to week 12 (including…","Proportion of eyes classified as suboptimal responders at Week 12 — 12 weeks"],"design_description":"NON RANDOMIZED · SEQUENTIAL · OTHER · NONE","source_has_results":false},"controlled_terms":["Age Related Macular Degeneration","Faricimab","Ranibizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07249216","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-07-18 to 2029-07-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.796Z","intervention":["Faricimab","Ranibizumab"],"participants":117,"study_design":"NON RANDOMIZED · SEQUENTIAL · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Difference in vitreous biomarker concentrations between responders and non-responders — 12 weeks","Change in concentration of inflammatory and angiogenic biomarkers in vitreous humor from baseline to week 12 (including…","Proportion of eyes classified as suboptimal responders at Week 12 — 12 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/28325","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}